Journal of Zhejiang University-SCIENCE B(Biomedicine Biotechnology)2023 24(2):130-142www.jzus.zju.edu.cn:www.springer.com/journaV/11585E-mail:jzus_b@zju.edu.cnGuidelinehttps://doi.org/10.1631/jzus.B2200466间Check for updatesChinese consensus guidelines for therapeutic drug monitoring ofpolymyxin B,endorsed by the Infection and ChemotherapyCommittee of the Shanghai Medical Association and theTherapeutic Drug Monitoring Committee of the ChinesePharmacological SocietyXiaofen LIU,Chenrong HUANG,Phillip J.BERGEN3,Jian LP,Jingjing ZHANG,Yijian CHEN',Yongchuan CHEN',Beining GUO',Fupin HU',Jinfang HU',Linlin HU,Xin LI',Hongqiang QIU",Hua SHAO,Tongwen SUN,Yu WANG',Ping XU1,Jing YANG,Yong YANG",Zhenwei YU,Bikui ZHANG,Huaijun ZHU,Xiaocong ZUOM,Yi ZHANG,Liyan MIAO Jing ZHANG'Institute of Antibiotics.Hushan Hospital.Fudan University/Key Laboratory of Clinical Pharmacology of Antibiotics.National HealthCommission of the People 's Republic of China/National Clinical Research Centre for Aging and Medicine,Huashan Hospital,FudanUniversity:Shanghai 200040.ChinaDepartment of Clinical Pharmacology:the First Affliated Hospital of Soochow University/Institute for Interdisciplinary Drug Research adTranslational Sciences,College of Pharmaceutical Science,Soochow University.Suzhou 215000.ChinaBiomedicine Discovery Institute and Department of Microbiology:Monash University:Melbourne,VIC 3800.Australia'The Southwest Hospital of Army Medical University:Chongqing 400038 ChinaThe First Affiliated Hospital of Nanchang University:Nanchang 330006.ChinaZhongda Hospital Southeast University.Nanjing 210009.ChinaThe Third Hospital of Changsha.Changsha 410035.ChinaFujian Medical University Union Hospital.Fuzhou 350001.ChinaThe First Affiliated Hospital of Zheng-hou University:Zheng-hou 450052.ChinaThe Second Xiangya Hospital of Central South University:Changsha 410011.China"People's Hospital of Sichuan Province.Chengdu 610072.ChinaPSir Run Ru Shrw Hospital.School of Medicine.Zhejiang University.Hang-hou 310020.ChinaNanjing Drum Tower Hospital.Nanjing 210008.ChinaThe Third Xiangya Hospital of Central South University:Changsha000.ChinaTiaryin First Central Hospital.Tianjin 300190.ChinaResearch Ward of Huashan Hospital.Fudan University:Shanghai 200040.ChinaAbstract:Polymyxin B,which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections,becameavailable in China in Dec.2017.As dose adjustments are based solely on clinical experience of risk toxicity,treatment failure,and emergence of resistance,there is an urgent clinical need to perform therapeutic drug monitoring(TDM)to optimize the useof polymyxin B.It is thus necessary to standardize operating procedures to ensure the accuracy of TDM and provide evidencefor their rational use.We report a consensus on TDM guidelines for polymyxin B,as endorsed by the Infection and ChemotherapyCommittee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese PharmacologicalSoc
